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Abstract: The postulated transition of Bis-Maltolato-OxoVanadium(IV) (BMOV) from its 
inactive trans- into its cis-aquo-BMOV isomeric form in solution was simulated by means of 
computational molecular modeling. The rotational barrier was calculated with DFT – B3LYP 
under a stepwise optimization protocol with STO-3G, 3-21G, 3-21G*, and 6-31G ab initio basis 
sets. Our computed results are consistent with reports on the putative molecular mechanism of 
BMOV triggering the insulin-like cellular response (insulin mimetic) as a potent inhibitor of the 
protein tyrosine phosphatase-1B (PTP-1B). Initially, trans-BMOV is present in its solid dosage 
form but in aqueous solution, and during oral administration, it is readily converted into a mixture 
of “open-type” and “closed-type” complexes of cis-aquo-BMOV under equilibrium conditions. 
However, in the same measure as the “closed-type” complex binds to the cytosolic PTP-1B, it 
disappears from solution, and the equilibrium shifts towards the “closed-type” species. In full 
accordance, the computed binding mode of cis-BMOV is energetically favored over sterically 
hindered trans-BMOV. In view of our earlier report on prodrug hypothesis of vanadium organic 
compounds the present results suggest that cis-BMOV is the bioactive species.
Keywords: vanadium compounds, diabetes mellitus, molecular modeling, computational 
quantum chemistry, PTP-1B
Introduction
Vanadium is actually known as a trace element, essential for higher organisms 
although deficiency symptoms in humans have not yet been clearly identified 
(Guevara 1996). Trapping free oxygen radicals that might cause cardiac problems, 
it acts as a biological antioxidant and shows antitumoral activity (Scior et al 2005). 
Bis-Maltolato-OxoVanadium(IV) (BMOV) is under investigation in other pathologi-
cal processes induced by uric acid, such as vascular endothelial dysfunction (Jindal 
et al 2007).
The development of innovative vanadium compounds against diabetes mellitus 
(DM) has attracted much pharmaceutical interest during the last decades (Saatchi et al 
2005). In the light of desired clinical advantages of a novel orally administered drug with 
selective insulin-like effects, a considerable impact on the patients’ health, their insulin 
injection-related long-term complications, or reduced side effects compared to other 
oral antidiabetics, can be expected (Zhang et al 2008). Besides our review with critical 
details on the protein tyrosine phosphatase (PTPase) inhibition, the pharmacodynamical 
behavior of organic vanadium compounds, their complex stabilities and inconclusive 
role as prodrugs for simpler inorganic vanadium ions in combination with toxicity data, 
it is noteworthy here to add newer reports on pharmacological ﬁ  ndings (Scior et al 
2005). In 2007 the action mechanism on a molecular level was studied in BMOV-treated 
cell cultures. It was conﬁ  rmed that BMOV enhanced the tyrosine-phosphorylation Drug Design, Development and Therapy 2008:2 222
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of upstream insulin-signaling proteins including the insulin 
receptor (Bose et al 2007). Heinemann and colleagues 
(2003) examined the pharmacokinetics of insulin mimetic 
inorganic vanadium ions: mainly vanadate (+V, 80%) 
and other oxidation states. Their study in healthy humans 
after administration of a single intravenous dose revealed 
that the apparent volume of distribution was of the order 
of 0.6 L/Kg. A long terminal half-life dominates (80%) 
the excretion phase. It is responsible for the typical heavy 
metal accumulation of vanadium in tissues such as liver, 
kidneys, bone, and spleen (Heinemann et al 2003). Most 
recently, another pharmacokinetics study in rats evaluated 
positively the therapeutical potential of BMOV as an oral 
glucose-lowering drug candidate. BMOV was rapidly 
absorbed, widely distributed in various tissues but only 
slowly eliminated from plasma due to accumulation to a 
greater extent in bone tissue. The intragastric bioavailability 
was around 25% of the initial doses. Signiﬁ  cant decrease 
of glucose concentrations in plasma was observed in 
hyperglycemic diabetic rats (Zhang et al 2008).
Among the protein-tyrosine phosphatases, PTP1B has 
received much attention due to its role as a negative regulator 
of insulin signaling (Elchebly 1999; Cheng et al 2002). On 
one side the protein tyrosine phosphatase-1B (PTP-1B) is 
highly expressed in insulin-resistant persons. The absence 
of PTP-1B in genetically modiﬁ  ed mice, on the other side, 
immunizes them against obesity and diabetes, even with rich 
and fatty diets. Clearly, a selective control of the biological 
function of PTP1B is a challenging task, and an inhibitor 
must not only efﬁ  ciently bind to the speciﬁ  c target enzyme 
but also do so without impeding the catalytic behavior of 
closely related enzymes. In Figure 4 of our review we have 
already reported on the alignment studies to elucidate the 
regiospeciﬁ  city of PTP1B (Scior et al 2005). The design of 
small molecule PTP1B inhibitors to treat type II diabetes has 
received considerable attention (Groves et al 1998; Wang 
et al 2000; Shen et al 2001; Doman et al 2002; Patankar 
and Jurs 2003; Sun et al 2003; Szczepankiewicz et al 2003). 
Vanadium compounds have been known to mimic the effects 
of insulin by inhibition of tyrosine phosphatases. Based on 
such observations that vanadate (oxo complexes of vanadium 
with oxidation state +V) electronically and structurally 
imitates phosphate, and phosphorylated proteins constitute 
the substrates of PTP-1B, vanadium-coordinated compounds 
should be capable of blocking PTP-1B upon competitive 
replacement of the natural substrates. This is one of the 
possible hypotheses of the reaction mechanisms for vanadium 
compounds with insulin-like activities (Scior et al 2005). 
In addition, more recent papers explore these mechanisms 
in further detail (Zborowski et al 2005; Adachi et al 2006). 
The discovery of the insulin-like activity (insulin-mimetics) 
of vanadate ([VO4]3− or [H2VO4]−) (Shechter and Karlish 
1980), has ushered in a new era of antidiabetes research with 
new oxovanadium coordination complexes with inhibitory 
activities against protein-tyrosine phosphatases (PTP-1B) 
(Huyer et al 1997), albeit not selectively. The next generation 
compounds have been based on organic vanadium complexes 
in search of higher target selectivity or less toxicity. How-
ever, some vanadium compounds have a great plethora of 
intrinsic enzyme afﬁ  nities because of their phosphate-like 
physicochemical behavior: bio-isosterism (Scior et al 2005). 
Hence, it is of paramount importance whether the insulin-
mimetic effect can be dissociated from the unwanted side 
effects based on phosphate imitation (Scior et al 2005). The 
insulin-mimetic activity of certain vanadium coordination 
compounds has been well documented (Thompson and Orvig 
2000), in particular, the improved glucose uptake and biosyn-
thesis of glycogen as well as the inhibition of gluconeogenesis 
or lipolysis (Shechter et al 1998). In addition, speciﬁ  c bio-
molecular targets regarding the aforementioned effects have 
been identiﬁ  ed as protein phosphatases (Posner et al 1994; 
Crans and Tracey 1998; Cuncic et al 1999; Tracey 2000), 
whereas neither insulin receptor nor GLUT2/GLUT4 path-
ways are directly concerned as targets (Goldwaser et al 2000). 
In particular, Bis-Maltolato-OxoVanadium(IV) (BMOV or 
[VO(ma)2] with central atom = V4+; and ma = monoanion 
maltolate) has one of the highest antidiabetic activities among 
the known insulin-mimetics with vanadium coordination. 
Especially, BMOV was used to improve insulin sensitivity 
(Truett 2006). Syntheses in nonaqueous solvents always yield 
trans-BMOV, while in water trans-and cis-aquo forms of 
BMOV are present due to interconversion (Figure 1).
Both forms have to be tested in bio-assays for their 
biological relevance. Hence, the exact molecular mechanism 
of BMOV still remains unknown (Liboiron 2005). The work 
also aims at studying the rotational barrier with its transition 
state because so far, no crystal structure of BMOV bound 
to PTP-1B has been reported (PDB last visited August 8th, 
2008). Intriguingly, in 2003 a report presents the binding 
of a trigonal-bipyramidal vanadium oxide to the active 
site of PTP-1B although BMOV was incubated with the 
enzyme at the beginning of the crystallization (Peters et al 
2003). Thus, whether BMOV would constitute a sort of 
prodrug (with an inorganic oxovanadium complex as its 
bioactive form) or BMOV itself might reach the binding cleft 
(Katherine et al 2006), constitutes the scientiﬁ  c motivation Drug Design, Development and Therapy 2008:2 223
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for the present in silico simulations combining geometry 
prediction of the ligand and its docking into the suggested 
target. In this context we devised ab initio calculations to 
elucidate BMOV geometries and related structures.
The overall goal was to gain more insight about its 
possible bioactive structure by modeling an amenable 
binding mode of BMOV and related oxovanadium 
complexes applying adapted force ﬁ  eld techniques from 
the literature.
Material and methods
The energy minimization and unbiased, manual docking of 
vanadium complex into the enzyme PTP-1B was conducted 
in ﬁ  ve steps on a SGI 02 work station with 126 MB RAM 
(Silikon 2001). In general, vanadium compounds possess a 
higher diversity in their oxidation states as in their geometry. 
Cundari and colleagues had already demonstrated good 
modeling accuracy using semiempirical quantum chemistry 
and even molecular mechanics MM2 force ﬁ  elds (Cundari 
et al 1997, 1998). Other authors applied quantum chemical 
methods (Zborowski et al 2005). Since both have been used 
successfully, we combined them in our joint study.
(1) We adapted the available Tripos force ﬁ  eld (FF) (Sybyl; 
Tripos Inc., St. Louis, MO, USA) and validated it 
against Cundari’s test series, which also contains cis-and 
trans-BMOV (Table 1).
(2) The Brookhaven PDB database (Berman et al 2000) 
was searched for crystal structures of PTP-1B in active 
conformation (the “open” state) with docked ligands 
reﬂ  ecting some structural patterns: tetraoxo-complexes 
or aromatic “wings” (Groves et al 1998).
(3) The atoms of the target proteins were loaded with 
Kollman_united pre-calculated charges (Tripos Inc.) 
while the charges of vanadium ligands were derived from 
our ab initio calculations (Gaussian 1998).
(4) The geometry optimization was tailored to model the 
aqueous medium in a simpliﬁ  ed approach by simulating 
the dumping effects of solvent molecules on electrostatic 
interaction in the binding groove: distance-dependent 
dielectric constant (ε = 40); nonbonded cut off at 8 Å; 
conjugate gradient algorithm: Powell, and terminal criteria: 
energy change: of 0.2 KJ/mol (Tripos Inc.).
(5) The ﬁ  nal docked poses were compared to tungstate 
(WO4
− sodium salt) bound to human PTP-1B (Barford 
et al 1994).
Calculations of the cis-trans conversion were carried out 
on two DELL-computers (Dimension 2400, with Pentium 
IV 2.8 GHz processors, 256 MB RAM, and 40 GB hard 
discs), using the Gaussian 98 electronic structure software 
(Gaussian, Inc., Wallingford CT, USA), and the ChemOfﬁ  ce 
2000 program (CambridgeSoft, Cambridge, MA, USA) to 
visualize the results. In order to draw electronic-density and 
electrostatic-potential graphics, the ArgusLab software has 
been used (ArgusLab 2005). Together with the ChemOfﬁ  ce 
program, both BMOV structures have been generated at 
the B3LYP (Becke 1993) DFT level, choosing a quadratic 
convergence criterion (SCF = QC). With these initial 
geometries, STO-3G single-point energy calculations have 
been performed, yielding some reference parameters of 
both species. Subsequently, a stepwise optimization of 
both chemical structures has been carried out by using 
the following basis sets: STO-3G, 3-21G, 3-21G*, and 
6-31G. Having terminated the optimization process, 
frequency calculations for each structure characterized the 
corresponding energy minimum type (ie, a global, local 
or intermediate minimum). Considering the biological 
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Figure 1 Structural representation of both isomers of BMOV in solution: (left) trans-BMOV, (right) the cis-acuo species where a solvent water moiety is attached to the 
central metal atom in the place of the electron lone pair. Despite the formal change in coordination geometries (trigonal bipyramidal to octahedral) due to the change of ligand 
number from 5 to 6 the over-all structure remains unchanged.Drug Design, Development and Therapy 2008:2 224
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activity of BMOV, aqueous solvent effects were taken into 
account. Therefore, we employed the Gaussian 98 dipole 
and polarization options.
In addition, DFT calculations using the B3LYP/6-311G* 
approach (Gaussian 03 program system; Gaussian Inc.) 
were carried out for trans- and cis-BMOV as well as for 
the transition state connecting the both isomers, in order to 
determine the relative stabilities of these structures.
Results and discussion
To postulate a viable mechanism one has to cope with a 
principle obstacle: while cis-aquo-BMOV is the observed 
active species, the isomeric trans-BMOV is its administered 
solid form. The ﬁ  rst part of our study simulates the block-
ing of PTP-1B by either cis-or trans-BMOV. The calculated 
active conﬁ  guration (cis or trans) is thought to suppress the 
intracellular insulin effects, therein assisting the cells in need 
of an adequate insulin response.
Docking results
To avoid blind docking, we conducted a PDB search for 
the most related crystal structure to BMOV and found a 
tetraoxo analogue to vanadate, called tungstate. It binds to 
the active site of the protein tyrosine phosphatase1B (PDB 
code: 2hnq) (Figure 2).
Applying the adapted Tripos FF (Tripos Inc.), the 
geometric structures of the BMOV and of some related 
complexes (Cundari et al 1997, 1998) were predicted 
correctly (Table 1). Prior to the unbiased docking of BMOV 
into the PTP-1B targets (PDB codes: 1bzc, 1bzh) (Groves 
et al 1998), the ligands were removed. In good agreement 
with reported data, trans-BMOV meets steric hindrance what-
ever the docked poses around the central atom position. But 
for the central atom of cis-BMOV, the computed pose is very 
similar to that described for tungstate. The ﬁ  nal coordinates 
of the central atom on BMOV and of inorganic vanadate 
resulted in practically identical coordinates as compared to 
the crystallographic position of tungstate (PDB code: 2hnq) 
(Barford et al 1994): W in [WO4]− : x = −1.1596, y = −0.0977, 
z = +9.2017 cf. V in [VO4]3−: x = −1.5147, y = −0.8434, 
z = +10.3426. For validation purpose, tungstate was 
successfully docked back into its crystallographic position 
using the same force ﬁ  eld conditions (cf. −220 KJ/mol 
for [WO4]−). This successful validation of the test system 
Table 1 Geometrical quality of the models generated under our adapted Tripos force ﬁ  eld as compared to the reference structures 
published by Cundari and colleagues (1997). The geometrical similarity of the superimposed complexes is expressed as the root means 
square of sum for all distance differences between equivalent atoms (model vs reference) divided by the number of atoms (RMSD). RMSD 
itself can be seen as a descriptor of geometrical errors against a reference structure (template). If the RMSD lies under 0.2 Angstroms 
the small molecule is practically identical to its original template structure.
Vanadium complex RMSD [Angstroms] (comments)
cis-BMOV 0.18
trans-syn-BMOV 0.13
[V+4O(acac)2] 0.13
[V+4O(acen)2] cis 1.07 (with lone pair electrons as formal ligands some atoms become twisted 
and are “optimized” into a new orthohexagonal geometry due to the higher 
coordination number with formal LPs predeﬁ  ned V-coordination geometries) 
0.35 (without formal lone pair electrons attached to V)
[V+4O(acen)2] trans 0.07
[V+4O(catecholate)2]2− 0.07
[V+4O(SCH2CH2S)2]2− crossed 0.12
[V+4O(SCH2CH2S)2]2− parallel 0.11
[V+5(O)2(dpc)]− (DPOV) 0.08
[V+5(O)2(F)(oxalate)]2− 0.10
[V+4(O)(dpc)(H20)2] 0.12
[V+4(O)(H20)5]2+ 0.12
[V+5(O)2(ox)2]3− cis 1.23 (formal up-down turn of coordinated atoms, ie,the atoms change 
position swinging through the mirror plane. No LP correction possible, cf. cis 
form of   V + 4O(acen)2] )
[V+5(O)2(ox)2]3− trans 0.17Drug Design, Development and Therapy 2008:2 225
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evidences that steric and electrostatic forces mainly control 
this anion binding. It is noteworthy that hydrophobic and 
solution effects (entropy) are not quantiﬁ  ed during manual 
docking in the Tripos FF. Notwithstanding, the nonbonded 
electrostatic and van der Waals terms were combined in 
a qualitative manner with the insight obtained from other 
docking tools (Ludi, FlexX, Autodock) (Coupez and Lewis 
2006). For instance, in Autodock with it’s A(romatic) atom 
type and solvation descriptors for hydrophobic effects, 
π-π and cation-π interactions of neutral BMOV were 
recognized even without a set of vanadium parameters at hand 
(Castellano et al 2003). The calculated energy (interpreted 
with precaution for its limited parameterization for bonded 
and nonbonded electrostatic/steric terms) for docked 
cis-BMOV was −136 KJ/mol, which lies in good proximity 
to the peptide ligands found in 1bzc and 1bzh after crystal 
strain was released by full geometry optimization (Groves 
et al 1998): −179 KJ/mol and −203 KJ/mol, respectively. 
The bioactivity pattern of BMOV is a hybrid: on the one 
side, it has aromatic contacts in common with the peptide 
ligands, on the other side it establishes the typical hydrogen 
bon network of other nonpeptide small ligand complexes 
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Figure 2 Structural display of reference crystal structure of protein tyrosine phosphatase1B (PDB code: 2hnq). Tungstate, a tetraoxo homologue to vanadate, is bound to 
the active site (see text). Except for a few labeled amino acids the protein is represented by its backbone with helical parts in red, turns and loops in white, and beta strands 
in light blue color.Drug Design, Development and Therapy 2008:2 226
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through the many oxo groups (Figure 3). Figure 8 is a 
schematic drawing of the binding-relevant amino acids 
(pharmacophore): TYR46, PHE182, SER216, ALA217, 
GLY218, ILE219, GLY220, and ARG221. Particularly, the 
residues SER216, ALA217, GLY218, ILE 219, GLY220, 
and cationic ARG221 participate in binding of [WO4]− as 
an inorganic tetraoxo-monoanion whereas some of them 
(SER216, ALA217, GLY220, ARG221) and others (anionic 
ASP181, aromatic PHE182 and TYR46) interact with for-
mally uncharged, aromatic cis-BMOV. Moreover, a π-π 
interaction can be observed between one maltolate ring on 
BMOV with TYR46 (Figure 3 and 8). In addition, positively 
charged ARG221 attracts the other maltolate anion in a 
typical cation-π interaction (Castellano et al 2003). Since both 
identical maltolate rings on docked BMOV enhance binding 
strength, but in two different ways this “wing”-symmetry 
can be broken up in future drug proﬁ  ling in search of higher 
binding selectivity. In this respect, we had already aligned 
the PTP-1B against other phosphatase family members and 
have reported the results of conserved and unique amino 
acids at the binding site elsewhere (Scior et al 2005). As 
a ﬁ  nal step in docking to conﬁ  rm our working hypothesis, 
cis- and trans-BMOV were docked into PTP-1B. There is 
computed evidence that cis-aquo-BMOV can be favorably 
placed into the active site of the target enzyme, while trans-
BMOV cannot enter there due to energetically high barriers 
(Figure 3).
Due to the absence of imaginary frequencies, the ab 
initio optimization process for trans-BMOV yielded a global 
minimum (Figure 4) on the potential energy surface. Moreover, 
comparing both optimization results with and without solvent 
effects, respectively, we observed only marginal deviations. 
Thus, we consider this structure to be stable.
With respect to the cis-aquo-BMOV geometry, 
generated by stepwise single-point energy optimization, we 
obtained two structures: The ﬁ  rst one, termed “closed-type 
cis-aquo-BMOV” (Figure 5), maintains the V-O(maltol) 
bonding. Theoretically, this structure represents a local 
minimum, due to its three imaginary frequencies, which 
might stem from a geometrical distortion generated by the 
water ligand; taking into consideration the solvent effect, this 
structure remains stable, too. The vacuum structure, however, 
seems to be slightly preferred.
The second structure (the stepwise optimization result 
using the 6-31G basis set) is the so-called “open-type 
cis-aquo-BMOV” (Figure 6). Showing the same energy as 
“closed-type cis-aquo-BMOV”, this structure represents a 
global minimum, since no imaginary frequencies occurred. 
The solvent interaction option conﬁ  rms that “open-type 
cis-aquo-BMOV” can be considered being stable throughout, 
with a slight tendency towards the aqueous phase.
Energy values obtained for the three species indicate, 
that in aqueous solution and room temperature (ie, under 
physiological conditions) the conversion from trans-BMOV 
Figure 3 Result of the computed binding mode of the “closed-type cis-aquo-BMOV” complex at the active site (stick representation of 3D-model). Element color code: white 
C, light blue H, red O, dark blue N, yellow S or V, magenta LP.Drug Design, Development and Therapy 2008:2 227
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Figure 4 Results of the full optimization for the trans-BMOV complex: (Top left) Tabular listing of total energies (in Hartree) for different basis sets. The asterisk marks a local 
energy value. (Plot below) Total energy variation graphics (in Hartree): black: without solvent; red: with solvent; blue: interaction model with a PCM-type solvent. (Right side) 
Schematic plot of the optimized structure.
c
c
c
c
c
c
c
c
c
c
c
c
o
o
o
o
o
o
o
OPT DIP PCM
−1925
−1935
−1930
−1920
−1915
−1910
−1905
−1900
−1895
−1933.6924618
−1924.1469983
−1924.1469983
−1911.2314114
−1933.6959770
−1924.1501056
−1924.1501056
−1911.2325419
−1933.6927583
−1924.1499732
−1924.1499732
−1911.3966987
−1911.2523053*
BASE OPT DIPOLE PCM
STO-3G
STO-3G
3-21G
3-21G*
6-31G
−1970
−1975
−1980
−1985
−1990
−1995
−2000
−2005
−2010
−2015
OPT DIP PCM
BASE OPT DIPOLE PCM
STO-3G
STO-3G
3-21G
6-21G
3-21G*
−1986.0011530*
−1986.7602757
−2000.1630858
−2000.1630858
−2010.1110448
−1986.6532272
−1999.9972020
−1999.9972020
−2009.9111978
−1986.6479353
−1999.9901946
−1999.9901946
−2009.9022315
o
o
o
c
c
c
c
c
c
c
c
c
c
c
o
o
o
Figure 5 Results of the full optimization for the “closed-type cis-aquo-BMOV” complex: (Top left) Total energies (in Hartree) listed for different basis sets. The asterisk marks 
a local energy value. (Plot below) Total energy variation graphics (in Hartree): indigo blue: without solvent; green: interaction model with a dipolar solvent; blue: interaction 
model with a PCM-type solvent. (Right side) Schematic plot of the optimized structure.Drug Design, Development and Therapy 2008:2 228
Scior et al
to cis-aquo-BMOV is thermodynamically possible. The 
“open-type cis-aquo-BMOV” hereby seems to be the stable 
intermediate in kinetic equilibrium with the “closed-type 
cis-aquo-BMOV” form. To ﬁ  nd out which of the two species 
interacts with the enzyme we determined both corresponding 
electrostatic potential surfaces by means of the Arguslab 
program (ArgusLab 2005). The result conﬁ  rms that “closed-
type cis-aquo-BMOV” shows a negative electrostatic 
potential of higher absolute value at the vanadium position and 
its close environment (Figure 7). It thus turns out to be more 
nucleophilic compared to the “open” structure, with higher 
afﬁ  nity to the catalytic center of the enzyme PTP-1B.
Finally, the geometries of trans- and cis-aquo-BMOV 
(“open-type”) were optimized at the B3LYP/6-311G* level of 
theory. Subsequent frequency calculations demonstrated, that 
both forms represent minima, ie, stable structures, on the energy 
hypersurface. The cis isomer is lower in energy by 5.6 KJ/mol as 
compared with the trans-BMOV, thus being the global minimum. 
The search for a transition state connecting the both forms along 
the reaction coordinate resulted in a structure possessing one 
imaginary frequency, ie, a ﬁ  rst order saddle point, being higher 
in energy by 21.1 KJ/mol with respect to the global minimum.
Conclusion
The goal of the present in silico study is to theoretically address 
the missing explanation of a trans-cis conversion of BMOV. 
To our best knowledge, it generates the ﬁ  rst molecular 
binding mode model concerning the insulin-mimetic activity 
of BMOV. It also elucidates the stereochemical require-
ments of BMOV as an inhibitor to the biomolecular target 
site. In aqueous solution the administered compound trans-
BMOV is converted into an “open-type cis-aquo” species 
of BMOV, which itself is in equilibrium with another 
“closed-type” form of cis-aquo-BMOV. The postulated 
binding mode for BMOV, ie,”closed-type cis-aquo-BMOV” 
complex, is fully consistent with in vivo studies on BMOV 
activity with respect to enzyme activity of PTP-1B: the 
group of McNeill reported that BMOV treatment reduced 
the activity of PTP I B by 25% in fatty treated rats (Moham-
mad et al 2002).
Our present work may lead to the detection of the 
activated complex upon forming a complex of cis-BMOV 
with a H2O moiety. It deﬁ  nes the energy barrier, which in 
turn may control the reaction speed. Our report may help 
other researchers to devise new calculations concerning this 
activated complex. To this end our modeling input and output 
data can be obtained by email.
In conclusion, we contribute with computed solutions 
to better understand the molecular recognition process 
and selectivity of nonpeptide insulin-mimetic vanadium 
complexes. To complete the picture, on a theoretical level 
it cannot be discarded that vanadium coordinated organic 
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Figure 6 Results of the full optimization for the “open-type cis-aquo-BMOV” complex: (Top left) Total energies (in Hartree) for the basis set 6-31G. (Plot below) Total energy 
bar graphics (in Hartree): blue: without solvent; red: interaction model with a dipolar solvent; yellow: interaction model with a PCM-type solvent. (Right side) Schematic plot 
of the optimized structure.Drug Design, Development and Therapy 2008:2 229
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Figure 8 Schematic viewing of our elaborated pharmacophore model with the active site of PTP-1B: binding- relevant amino acids are labeled according to the numbering 
scheme found in PDB entry: 2hnq. Not shown: upon blocking the enzyme PTP-1B, the insulin docked to its extracellular membrane receptor triggers the intercellular signal 
and the cell responds with normal glucose up-take. Boxed amino acids are not structurally depicted just labeled by their code for ﬁ  gure clarity.
Figure 7 Energy diagram of the computed cis-trans conversion mechanism for the bioactive BMOV in its “closed-type cis-aquo”-form. In aqueous solution, the administered 
compound, trans-BMOV, intermediately converts into the “open-type cis-aquo-BMOV” complex being in equilibrium with the “closed-type cis-aquo-BMOV”. Note, the activated 
transition complex of the reaction trans-BMOV + H2O remains hitherto unknown. NIR, normal insulin response; IR, state of insulin resistance.Drug Design, Development and Therapy 2008:2 230
Scior et al
compounds would also be prodrugs after re-arrangements 
with stronger chelators and following redox-reactions. Thus, 
whether BMOV or a simple (inorganic) tetraoxo compound is 
the ﬁ  nal bioactive species acting on target structure remains 
an open question and disserves further investigation.
Acknowledgments
For their pancreatic and extra-pancreatic exploration of our 
synthetic vanadium complexes special thanks are owed to 
Priv. Doz. Dr Nicolas Lembert, and Priv. Doz. Dr Reiner 
Lammers, at University of Tuebingen, Germany. For 
temporal work of TS and JAG at University of Tuebingen, 
Germany, and at GreenPharma, Orléans, France, grateful 
acknowledgments are given to Prof. Dr. S. Laufer, 
Dr D. Domeyer. Dr Q.-T. Do, and Dr Ph. Bernard. We 
also would like to acknowledge Dr P.H. Hernandez T. of 
VIEP – BUAP, as well as CONACYT (2007/52639) for 
their valuable support.
References
Adachi Y, Yoshikawa Y, Yoshida J, et al. 2006. Improvement of diabetes, 
obesity and hypertension in type 2 diabetic KKA(y) mice by 
bis(alli-xinato)oxovanadium(IV) complex. Biochem Biophys Res 
Commun, 345:945–50.
ArgusLab. 2005. ArgusLab 4.0.1. Mark A. Thompson. Planaria Software 
LLC, Seattle, WA.
Atkins PW, Friedman RS. 2003. Molecular Quantum Mechanics. Oxford 
University Press. Oxford, New York, Toronto.
Aznar CP, Deligiannakis Y, Tolis EJ, et al. 2004. ESE-ENDOR study and 
DFT calculations on oxovanadium compounds: Effect of axial anionic 
ligands on the 51V nuclear quadrupolar coupling constant. J Phys Chem, 
108:4310–21.
Barford D, Flint AJ, Tonks NK. 1994. Crystal structure of human protein 
tyrosine phosphatase 1B. Science, 263(5152):1397–404.
Becke AD. 1993. Density-functional thermochemistry. III. The role of exact 
exchange. J Chem Phys, 98:5648–52.
Bella SD, Lanza G, Gulino A, et al. 1996. Electronic structure of Bis 
(2, 4-pentanedionato-O; O’) oxovanaduim (IV). A photoelectron 
spectroscopy, electronic spectroscopy, and ab initio molecular orbital 
study. Inorg Chem, 35:3885–90.
Berman HM, Westbrook J, Feng Z, et al. 2000. The protein data bank. Nucl 
Acid Res, 28:235–42.
Bose S, Farah MA, Jung HC, et al. 2007. Molecular mechanism of bis(mal
tolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 
cells: impact of dexamethasone. J Mol Endocrinol, 38:627–49.
Bühl M. 2000. Density-functional study of vanadate-glycylserine isomers. 
J Inorg Biochem, 80:137–9.
Caballero CNA. 2003. Master Thesis in Chemical Sciences in Spanish 
language: Tesis de Maestría en Ciencias Químicas. Estudio Teórico de 
Compuestos de Vanadio con Actividad Tipo Insulina y su Interacción 
con la Enzima PTP-1B. Benemérita Universidad Autónoma de Puebla. 
Puebla, México.
Castellano RK, Diederich F, Meyer EA. 2003. Interactions with Arenes: 
Interactions with Aromatic Rings in Chemical and Biological 
Recognition. Angew Chem, 42:1210–40.
Coupez B, Lewis RA. 2006. Docking and scoring – theoretically easy, 
practically impossible? Curr Med Chem, 13:2995–3003.
Crans DC. 2000. Chemistry and insulin-like properties of vanadium(IV) and 
vanadium(V) compounds. J Inorg Biochem, 80:123–31.
Crans DC, Tracey AS, Crans DC. 1998. Vanadium Compounds: Chemistry, 
Biochemistry, and Therapeutic Applications. Washington, DC: 
American Chemical Society Symposium Series.
Cuncic C, Detich N, Ethier D, et al. 1999. Vanadate inhibition of protein 
tyrosine phosphatases in Jurkat cells: modulation by redox state. J Biol 
Inorg Chem. 4:354–9.
Cundari TR, Saunders L, Sisterhen LL, 1998. Molecular modeling of 
vanadium oxo complexes. a comparison of quantum and classical 
methods. J Phys Chem A, 102:997–1004.
Cundari TR, Sisterhen LL, Stylianopoulos CL, 1997. Molecular modeling 
of vanadium peroxides. Inorg Chem, 36:4029–34.
Cheng A, Dubé N, Gu F, et al. 2002. Coordinated action of protein tyrosine 
phosphatases in insulin signal traduction. Eur J Biochem, 269:1050–9.
Doman TN, McGovern SL, Witherbee BJ, et al. 2002. Molecular docking 
and high-throughput screening for novel inhitors of protein tyrosine 
phosphatase-1B. J Med Chem, 45:2213–21.
Elchebly M, Payette P, Michaliszyn E, et al. 1999. Increased insulin 
sensitivity and obesity resistance in mice lacking the protein tyrosine 
phosphatase-1B gene. Science, 283:1544–8.
Foresman JB, Frisch AE. 1998. Exploring Chemistry with Electronic 
Structure Methods: A Guide to Using Gaussian 98. Wallingford, CT: 
Gaussian, Inc.
Gracia L, Andrés J, Safont VS, et al. 2004. DFT study of the reaction between 
VO2+ and C2H6. Organometallics, 23:730–9.
Groves MR, Yao ZJ, Roller PP, et al. 1998. Structural basis for inhibition 
of the protein tyrosine phosphatase 1B by phosphotyrosine peptide 
mimetics, Biochemistry, 37:17773–83.
Goldwaser I, Gefel D, Gershonov E, et al. 2000. Insulin-like effects of 
vanadium; basic and clinical implications. J Inorg Biochem. 80:21–5.
Guevara JA. 1996. Una Semblanza de la Química Bioinorgánica del 
Vanadio. Revista Educación Química, 7:185–9.
Heinemann G, Fichtl B, Vogt W. 2003. Pharmacokinetics of vanadium in 
humans after intravenous administration of a vanadium containing 
albumin solution. Br J Clin Pharmacol, 55:241–5.
Huyer G, Liu S, Kelly J, et al. 1997. Mechanism of inhibition of 
protein-tyrosine phosphatases by vanadate and pervanadate. J Biol 
Chem, 272:843–51.
Jindal S, Singh M, Balakumar P. 2007. Effect of bis (maltolato) 
oxovanadium (BMOV) in uric acid and sodium arsenite-induced 
vascular endothelial dysfunction in rats. Int J Cardiol, 1:23–7.
Kallies B, Meier R. 2001. Electronic structure of 3d [M(H2O)6]3+ ions from 
ScIII to FeIII: A quantum mechanical study based on DFT computations 
and natural bond orbital analyses. Inorg Chem, 40:3101–12.
Katherine H, Thompson, Orvig C, 2006. Metal complexes in medicinal 
chemistry: new vistas and challenges in drug design. Dalton 
Trans, (6):761–4.
Larsen SC. 2001. DFT calculations of proton hyperﬁ  ne coupling constants 
for [VO(H2O)5]2+: Comparison with proton ENDOR data. J Phys 
Chem, 105:8333–8.
Levine IN. 2000. Quantum Chemistry. Upper Saddle River, NJ: Prentice Hall.
Liboiron BD, Thompson KH, Hanson GR, et al. 2005. New insights into 
the interactions of serum proteins with Bis(maltolato)oxovanadium
(IV): Transport and biotransformation of insulin-enhancing vanadium 
pharmaceuticals. J Am Chem Soc, 127:5104–15.
McQuarrie DA, Simon JD.1997. Physical Chemistry, a Molecular Approach. 
Sausalito, CA: University Science Books.
Mohammad A, Wang J, McNeill JH. 2002. Bis(maltolato)oxovanadium(IV) 
inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo. 
Mol Cell Biochem, 229:125–8.
Patankar SJ, Jurs PC. 2003. Classiﬁ  cation of inhibitors of protein tyrosine 
phosphatase 1B using molecular structure based descriptors. J Chem 
Inf Comput Sci, 43:885–9.
Peters KG, Davis MG, Howard BW, et al. 2003. Mechanism of insulin 
sensitization by BMOV (bis maltolato oxo vanadium); unliganded 
vanadium (VO4) as the active component. J Inorg Biochem, 96:321–30.
Pople JA. 1999. Quantum chemical models (Nobel Lecture). Angew Chem, 
38:1894–902.Drug Design, Development and Therapy 2008:2 231
Conversion of trans- to bioactive cis-BMOV
Posner BI, Faure R, Burgess JW, et al. 1994. Peroxovanadium compounds. 
A new class of potent phosphotyrosine phosphatase inhibitors which 
are insulin mimetics. J Biol Chem, 269:4596–604.
Saatchi K, Thompson KH, Patrick BO, et al. 2005. Coordination chemistry 
and insulin-enhancing behavior of vanadium complexes with maltol 
C6H6O3 structural isomers. Inorg Chem, 44:2689–97.
Scior JT, Guevara JA, Bernard P, et al. 2005. Are vanadium compounds 
drugable? Structures and effects of antidiabetic vanadium compounds: 
a critical review. Mini Rev Med Chem, 5:1–14.
Shechter Y, Eldberg G, Shisheva A, et al. 1998. Vanadium Compounds, 
Chemistry, Biochemistry and Therapeutic Applications. New York, 
NY: Oxford University Press.
Shechter Y, Karlish SJ. 1980. Insulin-like stimulation of glucose oxidation 
in rat adipocytes by vanadyl (IV) ions. Nature, 284:556–8.
Shen K, Keng YF, Wu L, et al. 2001. Acquisition of a speciﬁ  c and potent 
PTP1B inhibitor from a novel combinatorial library and screening 
procedure. J Biol Chem, 276:47311–9.
Sun JP, Fedorov AA, Lee SY, et al. 2003. Crystal structure of PTP1B 
complexed with a potent and selective bidentate inhibitor. J Biol Chem, 
278:12406–14.
Szczepankiewicz BG, Liu G, Hajduk PJ, et al. 2003. Discovery of a potent, 
selective protein tyrosine phosphatase 1B inhibitor using a linked-
fragment strategy. J Am Chem Soc, 125:4087–96.
Thompson KH, Orvig C. 2000. Design of vanadium compounds as insulin 
enhancing agents. J Chem Soc-Dalton Trans, 17:2885–92.
Tracey AS. 2000. Hydroxamido vanadates: aqueous chemistry and function 
in protein tyrosine phosphatases and cell cultures. J Inorg Biochem, 
80:11–6.
Truett GE. 2006. Prevention of diabetes by inhibition of tyrosine 
phosphatases. Exp Biol Med, 231:487–8.
Wang H, Lim KL, Yeo SL, et al. 2000. Isolation of a novel protein tyrosine 
phosphatase inhibitor, 2-methyl-fervenulone, and its precursors from 
Streptomyces. J Nat Prod, 63:1641–6.
Zhang SQ, Zhong XY, Chen GH, et al. 2008. The anti-diabetic 
effects and pharmacokinetic profiles of bis(maltolato)oxovan
adium in non-diabetic and diabetic rats. J Pharm Pharmacol, 
60:99–105.
Zborowski K, Grybos R, Proniewicz LM. 2005. Molecular structures of 
oxovanadium(IV) complexes with maltol and kojic acid: a quantum 
mechanical study. Inorg Chem Comm, 8:76–8.